Navigation Links
Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
Date:2/21/2008

s royalties from GSK on worldwide 3TC sales. GSK's worldwide sales of 3TC for the year to December 31, 2007 were $1,110 million, a decrease of 2% compared to the same period in 2006 (2006: $1,138 million), but a decrease of approximately 7% on a constant exchange rate basis. While the nucleoside analogue market for HIV has continued to grow, competitive pressures within the market have increased leading to a decline in 3TC sales.

In 2007 generic drug companies filed Abbreviated New Drug Applications ("ANDA") seeking approval for EPIVIR, COMBIVIR, ZEFFIX and EPZICOM in the US. Pursuant to the GSK/Shire license for lamivudine products, GSK has the right to enforce the licensed patents. In November 2007 GSK filed a patent infringement lawsuit against Teva Pharmaceuticals, Inc. (Teva) in the US District Court for the District of Delaware for infringement of one of the patents relating to COMBIVIR. The patent, which covers the combination of AZT and lamivudine to treat HIV, expires in May 2012. Teva had filed an ANDA with the FDA with a certification of invalidity, unenforceability and non-infringement of that combination patent. Teva did not challenge two other patents relating to COMBIVIR that expire in 2010 and 2016. The case is in its early stages.

ZEFFIX - Chronic hepatitis B infection

Royalties from sales of ZEFFIX for the year to December 31, 2007 were $41.0 million, an increase of 18% compared to the same period in 2006 (2006: $34.8 million). The impact of foreign exchange movements has contributed 8% to the reported growth; excluding favorable foreign exchange movements there has been an increase of 10% compared to the same period in 2006.

Shire receives royalties from GSK on worldwide ZEFFIX sales. GSK's worldwide sales of ZEFFIX for the year to December 31, 2007 were $341 million, an increase of 13% compared to the same period in 2006 (2006: $301 million). This increase was mainly due to strong growth in the Chinese market and favor
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire plc: Correction Re Website
2. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
3. Shire Engages Palio
4. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
5. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
6. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire plc: Board Changes
9. David Mott Appointed Non Executive Director at Shire
10. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
11. Shire Divests Non-Core Product Portfolio to Almirall
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 1, 2014  Spherix Incorporated (Nasdaq: SPEX) -- an intellectual ... monetization of intellectual property, announced today that the ... Uniden in the U.S. District Court for the ... has been rescheduled for November 10, 2014.  This ... The Court Order setting the Markman date was ...
(Date:10/1/2014)... 2014 As the world takes its first ... doubt that this century would mark the beginning of a ... medicine science. The fact that the world is experiencing a ... the scientific community. Almost half of these chronic conditions are ... prevented with medical care and intervention. While the world is ...
(Date:10/1/2014)... (PRWEB) September 30, 2014 Today ... initial round of grants for the Brain Research ... that aims to develop and revolutionize new methods ... of the human brain. This first round of ... year 2014 was allocated to more than 100 ...
(Date:10/1/2014)... 30, 2014 New applications of structures ... have evolved in nature over millennia are featured in ... for applications in biophotonics in the October issue ... journal is published by SPIE, the international society for ... of the peer-reviewed articles are accessible via open access. ...
Breaking Biology Technology:Markman Hearing Date for VTech and Uniden Litigation Now Set for November 10, 2014 2Fighting Mortality and Morbidity of Chronic Health Disorders during Open Access Week 2Fighting Mortality and Morbidity of Chronic Health Disorders during Open Access Week 3NIH Awards 15 Grants to CHI Members for BRAIN Initiative Research 2NIH Awards 15 Grants to CHI Members for BRAIN Initiative Research 3Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 2Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 3
... new microelectromechanical systems (MEMS) can benefit from a new ... and Technology (NIST) to measure a key mechanical property ... Youngs modulus of thin films not only for MEMS ... , Since 1727, scientists and engineers have used Youngs ...
... to high quality, fully annotated serum, tissue and blood ... available for Genomic ... Oncology Metrics, a,business that develops products and services ... Cureline Inc., a global,biosample management company dedicated to innovation ...
... 9 Novo Nordisk, a,healthcare company with an ... today announced the appointment of Alan C. Moses, ... is currently the,chief medical officer of Novo Nordisk ... the unique talent to integrate the science of ...
Cached Biology Technology:NIST develops test method for key micromechanical property 2Oncology Metrics and Cureline Announce Joint Marketing Agreement 2Oncology Metrics and Cureline Announce Joint Marketing Agreement 3Novo Nordisk Appoints Alan C. Moses as Chief Medical Officer Worldwide 2
(Date:9/30/2014)... to tetrachloroethylene (PCE) in drinking water may increase ... to a new study led by a Boston ... study, published in the journal Environmental Health ... pregnancies among 1,766 women in Cape Cod, Ma., ... to the early 1980s by the installation of ...
(Date:9/30/2014)... Fish can live in almost any aquatic environment on ... up many species are pushed to the limit. The ... could prove critical for how different species cope in ... the University of Gothenburg, published in the scientific journal ... Climate change continues apace thanks to increasing levels of ...
(Date:9/30/2014)... farm runoff in Hawaii is causing tumors in endangered ... study, published Tuesday in the peer-reviewed open-access journal ... up in algae that the turtles eat, promoting the ... internal organs. , Scientists at Duke University, the University ... (NOAA) conducted the study to better understand the causes ...
Breaking Biology News(10 mins):Contaminated water linked to pregnancy complications, BU study finds 2Shape up quickly -- applies to fish, too! 2Pollution linked to lethal sea turtle tumors 2Pollution linked to lethal sea turtle tumors 3
... world will gather March 20-22 at the University of ... change for global agriculture and recommend science-based actions to ... food, livelihood and sustainability. The Climate-Smart Agriculture Global ... builds on a 2011 international meeting on this theme ...
... SAN FRANCISCO Heart patients who can,t tolerate the ... option, according to a new study by researchers from ... Salt Lake City. Researchers found that pitavastatin, a ... attack, stroke and even death in up to 68 ...
... competition the Museum of Evolution at Uppsala University, Sweden, has ... Thunberg collection. The project will make the valuable plants available ... 350 years since Linnaeus,s disciple Carl Thunberg travelled with the ... Lanka and Java. In total he collected almost 28,000 plants ...
Cached Biology News:International conference to tackle climate-change threats to agriculture 2Researchers find alternative cholesterol-lowering drug for patients who can't tolerate statins 2Carl Thunberg's Japanese plants to be digitized 2
... Assay, 96 wells. ELISA.Specific for total ... MMP-3. No cross-reactivity with MMP-1, -2, -9. ... use with cell culture supernatant, serum, plasma ... to -30 C. Category: Drug Screening ...
... Dr. P Set from different human ... More organs maybe available upon request. ... items from the whole set, and ... price. All Dr. P Set ...
Homo sapiens inhibin, beta B (activin AB beta polypeptide) Antigen: Recombinant Protein(142~254aa)...
Self Closing Forceps...
Biology Products: